Future Care Finland is a platform that highlights Finnish innovations, technologies and applications that aim to facilitate customized patient care.
The focus of healthcare is transforming from traditional disease treatment to prediction and prevention of diseases while maintaining health and wellbeing. P4-healthcare* (from words Predictive, Preventive, Personalized and Participatory) represents a new paradigm of future healthcare, empowering individuals to take more active role in management of their health. Understanding genetic and lifestyle risk factors, self-monitoring and collection of health data, defining genotype to phenotype connections revealing underlying disease mechanisms and development of individualized treatment options, are currently being actively promoted and provide immense possibilities for future care.
Future Care Finland -platform describes some of the efforts that aim towards customized patients care. These examples are focused on future possibilities of customized cancer care. However, many of the themes and innovations are directly applicable to also other diseases.
The story behind Future Care Finland
At Medaffcon, we are devoted to providing means for data-driven decision-making in healthcare and working towards economically sustainable, effective and more individualized treatment care. We believe that Finland is at the forefront of developing tomorrow’s healthcare and mapping the treatment paths of the future. Future Care Finland was born from the desire to share these visions with all people interested in future healthcare and wellbeing.
See below our vision for customized treatment path, presented by Päivikki Hemmilä and Maija Wolf in Health Awards and Foresight Forum event, held in January 2018. The presentation introduces some of the existing and arising elements associated with the development of future cancer care.
Future Care Finland -platform is developed and maintained by Medaffcon. Medaffcon provides research and expert services for the needs of the pharmaceutical industry and healthcare actors. These include biobank and other RWE studies.